Effects of Casein Hydrolysate on the Systolic Blood Pressure and Serum Lipid Profiles in Spontaneously Hypertensive Rats

Jeong-Ryong Do*, Su-Yeon Back, Sang-Dong Lim, Hyun-Ku Kim, Ki-Seung Sung, and Chan-Kyu Han
Korea Food Research Institute, Seongnam, Kyunggi-do 463-746, Korea

Abstract

The effects of casein hydrolysate on blood pressure (BP) and serum lipid profiles were investigated in spontaneously hypertensive rats (SHR). Twenty-four 6-wk old male SHRs were assigned to 3 groups in a completely randomized design. Experimental groups were as follow: control, market milk group (MLG) and casein hydrolysate group (CHG). Reference blood pressure (RBP) showed average 198.94±1.46 mmHg. Blood pressure (BP) of CHG reduced 24 mmHg after 2 wk of treatment, but these increased after 3 wk. BP of CHG was significantly lower than BP of Control in experimental time (p<0.05). Serum lipid profiles were not differ significantly among groups (p<0.05). These data suggest that casein hydrolysate may beneficially improvement of blood pressure level in SHR.

Key words: casein hydrolysate, blood pressure, serum lipid, spontaneously hypertensive rat

Introduction

Recently, the new relationship between food and health has drawn considerable attention; of interest are the physiological functions of some food components against certain ailments. Among the functions, some foods are known to be effective in suppressing the development of hypertension, which suggests the existence of some components having pharmaceutical action on the regulation systems of blood pressure (Lee et al., 1999). Hypertension is a worldwide problem of epidemic proportions, which presents in 15-20% of all adults. Hypertension is known to induce such direct cardiac circulating diseases as cardiac incompetence, decrease in kidney function, cerebral apoplexy. Hypertension is the most serious and ubiquitous disease and its complications have may contribute to high risk (Do et al., 2007; Wu and Ding, 2001). Food proteins can act as an important source of biologically active peptides with antihypertensive. These peptides are inactive within the sequence of parent proteins, but they can be released by enzymatic proteolysis in vivo or in vitro. Angiotensin I-converting enzyme (ACE) can convert angiotensin I to angiotensin II which is known to be a strong vasopressor, besides inactivating bradykinin conducive to lowering blood pressure (Xuan et al., 2005). This enzyme also plays physiological roles in the regulation of local levels of other endogenous peptides, such as enkephalins, neurotensin, and substance P. Therefore, inhibition of ACE can reduce the activity of angiotensinII, but increase bradykinin and enkephalins levels, which results in lowering of blood pressure (Koike et al., 1977). Thus, inhibition of ACE results in a decrease of blood pressure. Peptides derived from Food protein have been well demonstrated having in vivo inhibitory activities on ACE and antihypertensive effects after oral administration or intravenous administration in animal experiments using spontaneously hypertensive rats (SHR) and in clinical trials (Li et al., 2004). Many ACE inhibitory peptides have recently been discovered from enzymatic hydrolysates of different food proteins such as garlic (Kim et al., 2005), egg albumen (Kim et al., 2003), buckwheat (Lee et al., 2000), soybean protein (Wu and Ding, 2001), and corn gluten (Suh et al., 2003). Casein shows relatively strong antihypertensive activity against SHR. The ACE inhibiting peptides obtained from trypsin hydrolysates of casein showed the effect of drop of blood pressure in intravenous injection, but there was no effect on oral experiment of trypsin hydrolysates to SHR in the results of Yamamoto et al. (1994). Previous studies have shown that the protein hydrolysate had a high ACE inhibitory activity and stable gastrointestinal protease resistance in vitro, but their in vivo activity needs to be explored at the...

*Corresponding author: Jeong Ryong Do, Korea Food Research Institute, Sungnam 463-746, Korea, Tel: 82-31-780-9240, Fax: 82-31-709-9876, E-mail: jordo@kfri.re.kr
same time (Lee et al., 1999). This study was investigated the hypertensive effect of casein hydrolysate and serum lipid profiles in spontaneously hypertensive rats.

**Materials and Methods**

**Casein hydrolysate**

7% Na-caseinate (Virak Co., Food grade, Busan, Korea) solution of distilled water and then each 1% protamex (Novozymes, Bagsvaerd, Denmark) and flavourzyme 500 MG (Novozymes, Bagsvaerd, Denmark) enzyme were added. The mixture hydrolyzed at 55°C for 4 h. The hydrolysis was stopped by heating at 80°C for 5 min (Fig. 1) (Do et al., 2007).

**ACE inhibitory activity assay**

ACE inhibitory activity was analyzed using a modified version of the method of Cushman and Cheung (1971). The sample (50 µL) and 50 µL Hip-His-Leu (Sigma, St. Louis, MO, USA) were dissolved into 0.1 M sodium borate buffer (pH 8.3) containing 0.3 M NaCl, and incubated with ACE (50 µL) at 37°C for 30 min. The reaction was stopped by adding 1 N HCl 250 µL. The resulting hippuric acid was extracted by addition of 1.5 mL ethyl acetate. After centrifugation (3000 rpm×5 min), 1 mL of the upper layer was transferred into a glass tube and evaporated at 120°C for 30 min. The hippuric acid was redissolved in 3 mL distilled water, and absorbance was measured at 228 nm using spectrophotometer (V-570, Jasco, Tokyo, Japan). The ACE used in this experiment was extracted from rabbit lung acetone powder (Sigma, St. Louis, MO, USA) 1 g with 0.1 M sodium borate buffer (pH 8.3) containing 0.3 M NaCl 10 mL at 4°C over night and centrifuging for 40 min at 4,000 rpm.

\[
\text{ACE inhibition (％)} = \frac{1 - \left( \frac{S_a - S_b}{C_a - C_b} \right)}{100}
\]

Sa: sample absorbance \quad Sb: absorbance of sample blank \quad Ca: control absorbance \quad Cb: absorbance of control blank

**Animals and diets**

6 wk-old male spontaneously hypertensive rats (SHR) were used from SLC (SLC, Inc., INASA Branch, Tokyo, Japan). SHRs, a model for genetic hypertension, exhibit higher hypertension than normal rats (Okamoto and Aoki, 1963). All rats were maintained at 18-20°C, 50% humidity, and 12 h on/off light cycle. All of the rats had free access to a standard diet (Table 1) and to drinking water (American Institute of Nutrition, 1977). After acclimation for 1 wk, SHRs were divided into groups of 8 rats. SHRs

<table>
<thead>
<tr>
<th>Table 1. Composition of basal diet</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ingredients</strong></td>
</tr>
<tr>
<td>Casein (feed grade CP 85%)</td>
</tr>
<tr>
<td>Corn starch</td>
</tr>
<tr>
<td>Dextrinized corn starch</td>
</tr>
<tr>
<td>Sucrose</td>
</tr>
<tr>
<td>Soybean oil</td>
</tr>
<tr>
<td>Cellulose (fiber)</td>
</tr>
<tr>
<td>Mineral mixture</td>
</tr>
<tr>
<td>Vitamin mixture</td>
</tr>
<tr>
<td>L-Cystine</td>
</tr>
<tr>
<td>Choline bitartrate</td>
</tr>
</tbody>
</table>

1) Contained per kg mixture; CaHPO₄ 500 g, NaCl 74 g, K₂C₂O₆·H₂O 220 g, K₂SO₄ 52 g, MgO 24 g, 48% Mn 3.5 g, 17% Fe 6.0 g, 70% Zn 1.6 g, 53% Cu 0.3 g, KIO₃ 0.01 g, Cr(K₂SO₄·12H₂O) 0.55 g and sucrose.

2) Contained per kg mixture; thiamin·HCl 600 mg, riboflavin 600 mg, pyridoxine·HCl 700mg, nicotinic acid 3 g, Vit.A 400,000 IU (Retinyl acetate), Vit.E(dl-α-tocopheryl acetate) 5,000 IU, Vit. D₃ 2.5 mg, Vit. K 5.0 mg and sucrose.
Effects of Casein Hydrolysate on the Systolic Blood Pressure

weighed in the average of 233 g and reference blood pressure (RBP) showed average 223.7±1.2 mmHg.

Experimental diet and conditions
The experimental diets were oral administration and drinking water feeding. The oral administration were randomly divided into 3 groups; Control group (no administration), ML group (oral administration of 2 mL market milk), CH group (oral administration of 10% casein hydrolysate in 2 mL milk). ML and CH groups had oral administration every morning. In drinking water feeding, SHRs were randomly divided into 2 groups; Control group, CH group was drinking beverage (1% casein hydrolysate in water). Intake quantity at 2 d once and beverage quantity everyday measured at the time when it is identical.

Blood pressure
The blood pressure of SHRs were assessed by measuring the systolic blood pressure (SBP) every weeks. The blood pressure monitor was used a mercury type sphygmomanometer (IITC Inc., Woodland Hills, CA, USA) in tail vein. RBP was measured before 3 d of casein hydrolysate feeding. Blood classification was assessed according to the standard of the clinical experiment (Han et al., 2003; Pfeffer et al., 1971).

Analysis of serum lipid contents
Blood samples were treated with ethylene diamine tetraacetic acid (EDTA). The collected blood samples were centrifuged for 10 min at 3000 rpm in 4°C, and the supernatant was transferred to an eppendorf tube and stored in a freezer until analysis (Jung et al., 2001; Kim et al., 2007). Serum concentration of total cholesterol (TC) and triglyceride (TG) were measured using kit (cholesterol/triglyceride reagent) of colorimetric assay (ADIVIA 1650, Bayer, Tokyo, Japan). High-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C) concentration were measured using kit (direct HDL-cholesterol/cholesterol LDL) of colorimetric assay (ADIVIA 1650/Hitachi 7180, Bayer, Tokyo, Japan) (Rader et al., 2003).

Statistical analysis
All results were expressed in mean±SE. Statistical analysis was done using Statistical Analysis System (SAS) program and significance of each group was verified by the Duncan's multiple range test and t-test. Results with $p<0.05$ were considered statistically significant.

Results and Discussion

ACE inhibitory activity
ACE inhibitory activity of casein hydrolysate was 86.8% (Table 2). Casein hydrolysates by protamex and flavourzyme 500MG at 55°C for 4 h showed promise in the development of a functional food for preventing hypertension. Do et al. (2007) have reported casein hydrolysate that casein hydrolysis degrees of flavourzyme 500MG, protamex, and mixture from 1% casein at 55°C for 4 h were 85.5, 88.5, and 93.5%. Yield (93.5%) and ACE inhibitory activity (86.8%) of casein hydrolysate by mixture of protamex and flavourzyme 500MG were the highest. Protamex had the highest activity among endopeptidase activities of hydrolytic proteases showed the same tendency as Kim et al. (2002). Furthermore, this result of ACE inhibitory activity was higher than 45.55% in casein hydrolysate by promod 192 (Kim et al., 2002).

Weight gain and food efficiency ratio (FER)
Weight gain and FER during the experimental periods were shown in Table 3. The relative weight gain was higher in control than the other groups, but there was no significant difference in total weight gain (Lee et al., 2000). FER did not show a significant difference among groups. In orally tube feeding, the gain weight of CH group was 60.24 g for 5 wk. The gain weight was higher in control than CH group. FER was control (0.097) and CH group (0.090). Therefore, casein hydrolysate is presumed that food source is used to safety (Park et al., 2000).

Ogawa et al. (2007) have reported that feeding of osthol was no significant in body weight and daily food intake with control, indicating that dietary osthol gives good growth as well as the control.

Blood pressure
The change in BP after oral administration of casein hydrolysate (2 mL) to SHR for 5 wk is shown in Fig. 2. The reference BP of 6 wk-old SHR was on an average 198.9 mmHg. The systolic blood pressure (SBP) of control during the experimental period was increased from 205 mmHg to 222.4 mmHg. When market milk was

| Table 2. Effects of casein hydrolysate on ACE inhibition activity |
|----------------------|------------------|
| Enzyme           | ACE inhibition (%) |
| No enzyme         | 1.5±0.01         |
| Mixture           | 86.8±0.01        |

1Casein hydrolysated using protamex and flavourzyme 500MG at 55°C for 4 h.
orally administered to SHR, SBP was increased from 198.6 mmHg to 215.4 mmHg. After oral administration of casein hydrolysate to SHR, SBP was decreased from 197.7 mmHg to 195.7 mmHg for 5 wk. A significant antihypotensive effect of casein hydrolysate was observed during the 5-wk experimental period in SHR. BP of SHR is generally increased with weight gain (Lee et al., 2000).

The BP during the experimental period was increasing in control and ML groups. But BP of ML group was lower than BP of control group. This result suggests that milk was effective to reduce the blood pressure in SHRs. The SBP of CH group was decreased to 24 mmHg compared to control at 2 wk after oral administration of casein hydrolysate. Generally, the decrease in BP of CH group was significant compared to control and ML groups. On the other hand, the change in BP after drinking water of casein hydrolysate to SHR for 5 wk is shown in Fig. 3. The reference BP of 6 wk-old SHR was on an average 202.0 mmHg. Fig. 3 shows the BP of CH group was significantly lower than the BP of control group at 3 wk after drinking water of casein hydrolysate. The casein hydrolysate in the blood suppressed the activity of angiotensin converting enzymes (ACE) in SHR. Several peptides derived from sour milk, a wheat germ hydrolysate, and a sardine muscle hydrolysate were well known to have ACE-inhibiting activities and to exhibit antihypertensive activities in experimental animals (Do et al., 2006). Ogawa et al. (2007) have reported that the increase of systolic blood pressure was significantly suppressed after 3 wk of feeding, indicating that dietary osthol exerted hypotensive activity in SHR. BP of CH group by oral administration was reduced 7.2 % after 2 wk of experimental period. And BP of CH group by drinking was reduced 7.5% after 3 wk of experimental period. BP of CH group was increased after 2 and 3 wk of administration (Fig. 2 and 3). This pattern of reduction in BP, within 2 wk and maintained afterward, was also observed in the Dietary Approach to Stop Hypertension

Table 3. Total gain and FER in SHR fed by orally market milk and 10% casein hydrolysate in milk for 5 wk

<table>
<thead>
<tr>
<th>Group</th>
<th>Body weight (g)</th>
<th>FER&lt;sup&gt;3&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>Final</td>
</tr>
<tr>
<td>Control</td>
<td>234.48±4.38*</td>
<td>300.87±5.43*</td>
</tr>
<tr>
<td>Milk&lt;sup&gt;1&lt;/sup&gt;</td>
<td>232.63±6.07</td>
<td>292.38±6.55</td>
</tr>
<tr>
<td>CH&lt;sup&gt;2&lt;/sup&gt;</td>
<td>235.86±3.80</td>
<td>296.19±4.69</td>
</tr>
</tbody>
</table>

Values are Mean±SD (n=8).

<sup>*</sup>Not significant.

<sup>1</sup>Milk was orally administered once a day for 5 wk.

<sup>2</sup>10% Casein hydrolysate in milk

<sup>3</sup>Food efficiency ratio (body weight/ food intake)

Fig. 2. The changes of systolic blood pressure in SHR fed by orally market milk and 10% casein hydrolysate in milk supplied 2 mL for 5 wk. Blood pressure was decreased by casein hydrolysate for 2 wk. The raising trends of blood pressure were resembled both control and milk groups. Values are the Mean±SD (n=8). BP: blood pressure *: 10% casein hydrolysate in milk.

Fig. 3. The changes of systolic blood pressure in SHR fed tap water and 1% casein hydrolysate in water for 5 wk. Blood pressure was decreased by casein hydrolysate for 3 wk. The raising trend of blood pressure was control. Data are the Mean±SD (n=8). BP: blood pressure *: 1% casein hydrolysate in water.
and AI in SHR. But TG was increase in ML and CH that casein hydrolysate had an improving effect of LDL-C significantly decrease after 5 wk (p<0.05). The comparison between 0 week and 5 wk was not significant (p>0.05). These data suggest that casein hydrolysate had a improving effect of LDL-C and AI in SHR. But TG was increase in ML and CH groups. Wu and Ding (2001) have reported that treatment with soy ACE inhibitory peptides and Captopril administration was no significant changes of content of serum lipids in SHR. Takai et al. (2004) have reported that treatment with an ACE inhibitor significantly correlation was observed between SBP and ACE activity in the aorta, but not in the plasma or other tissues such as the heart and brain.

In conclusion, we have demonstrated that casein hydrolysate produced potent antihypertensive effects in vitro and in vivo. It seems likely that casein hydrolysate would be a beneficial ingredient for a prophylactic and therapeutic treatment against hypertension and its related diseases.

Acknowledgement

This work was supported by Ministry for Food, Agriculture, Forestry and Fisheries, Korea.

References


Table 4. Serum lipid contents and AI in SHR fed by orally market milk and 10% casein hydrolysate in milk for 5 wk

(Unit: mg/dL)

<table>
<thead>
<tr>
<th>Group</th>
<th>TC (1)</th>
<th>TG (2)</th>
<th>HDL (3)</th>
<th>LDL (4)</th>
<th>AI (5)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 wk</td>
<td>5 wk</td>
<td>0 wk</td>
<td>5 wk</td>
<td>0 wk</td>
</tr>
<tr>
<td>Control</td>
<td>65.80±</td>
<td>68.40±</td>
<td>99.80±</td>
<td>126.40±</td>
<td>25.80±</td>
</tr>
<tr>
<td>Milk (6)</td>
<td>65.00±</td>
<td>67.73±</td>
<td>93.88±</td>
<td>147.33±</td>
<td>25.36±</td>
</tr>
<tr>
<td>CH (7)</td>
<td>61.13±</td>
<td>68.43±</td>
<td>84.63±</td>
<td>132.43±</td>
<td>24.38±</td>
</tr>
</tbody>
</table>

Values are Mean±SD (n=8). Same small superscripts are not significantly different by Duncan’s multiple range test (p>0.05).

Analysis of serum lipids

Serum lipid concentration and atherosclerotic index (AI; Kim et al., 2006) during oral administration of casein hydrolysate (2 mL) to SHR was shown in Table 4. In terms of serum lipids, total-cholesterol (TC) and LDL-cholesterol (LDL-C) concentrations were not significant among experimental groups. Triglyceride (TG) concentration of control was significantly lower than ML and CH groups (p<0.05). HDL-C was significantly different between ML (29.67 mg/dL) and control (28.00 mg/dL) (p<0.05). AI was lower in ML and CH groups compared to control (p<0.05). The comparison between 0 week and 5 wk was observed a significant difference in TC, TG, and HDL-C concentrations by paired t-test (p<0.05), except for LDL-C in control and CH groups. However, AI was a significantly decrease after 5 wk (p<0.05). These data suggest that casein hydrolysate had a improving effect of LDL-C and AI in SHR. But TG was increase in ML and CH groups. Wu and Ding (2001) have reported that treatment with soy ACE inhibitory peptides and Captopril administration was no significant changes of content of serum lipids in SHR. Takai et al. (2004) have reported that treatment with an ACE inhibitor significantly correlation was observed between SBP and ACE activity in the aorta, but not in the plasma or other tissues such as the heart and brain.

In conclusion, we have demonstrated that casein hydrolysate produced potent antihypertensive effects in vitro and in vivo. It seems likely that casein hydrolysate would be a beneficial ingredient for a prophylactic and therapeutic treatment against hypertension and its related diseases.

Analysis of serum lipids

Serum lipid concentration and atherosclerotic index (AI; Kim et al., 2006) during oral administration of casein hydrolysate (2 mL) to SHR was shown in Table 4. In terms of serum lipids, total-cholesterol (TC) and LDL-cholesterol (LDL-C) concentrations were not significant among experimental groups. Triglyceride (TG) concentration of control was significantly lower than ML and CH groups (p<0.05). HDL-C was significantly different between ML (29.67 mg/dL) and control (28.00 mg/dL) (p<0.05). AI was lower in ML and CH groups compared to control (p<0.05). The comparison between 0 week and 5 wk was observed a significant difference in TC, TG, and HDL-C concentrations by paired t-test (p<0.05), except for LDL-C in control and CH groups. However, AI was a significantly decrease after 5 wk (p<0.05). These data suggest that casein hydrolysate had a improving effect of LDL-C and AI in SHR. But TG was increase in ML and CH groups. Wu and Ding (2001) have reported that treatment with soy ACE inhibitory peptides and Captopril administration was no significant changes of content of serum lipids in SHR. Takai et al. (2004) have reported that treatment with an ACE inhibitor significantly correlation was observed between SBP and ACE activity in the aorta, but not in the plasma or other tissues such as the heart and brain.

In conclusion, we have demonstrated that casein hydrolysate produced potent antihypertensive effects in vitro and in vivo. It seems likely that casein hydrolysate would be a beneficial ingredient for a prophylactic and therapeutic treatment against hypertension and its related diseases.

Acknowledgement

This work was supported by Ministry for Food, Agriculture, Forestry and Fisheries, Korea.


(Received 2009.7.17/Revised 1st 2009.9.28, 2nd 2010.3.11, 3rd 2010.4.27/Accepted 2010.5.14)